Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease

Wilson, Barnabas; Samanta, Malay K.; Santhi, K; Kumar, K.P. Sampath; Paramakrishnan, Nallupillai; Suresh, B.

doi:10.1016/j.brainres.2008.01.039

Cited by 334 publications

(155 citation statements)

References 64 publications

Supporting

Mentioning

150

Contrasting

Unclassified

Order By: Relevance

“…However, limitation with its oral drug ( Pr Sandoz Õ ) delivery restricts the entry of drug into brain due to its hydrophilicity, thereby necessitating to improve it. Wilson and associates have worked on RHT-loaded poly(n-butyl cyanoacrylate) NPs for brain targeting through intravenous route but the results of surfactant-coated poly(n-butylcyanoacrylate) NPs showed possibility of distribution to non-targeted site (Wilson et al, 2008). Therefore, further investigation has been carried out to deliver a wide range of drugs to targeting areas of the body for controlled drug release and site-specific drug targeting by developing polymeric NPs.…”

Section: Rivastigminementioning

confidence: 99%

Insights into direct nose to brain delivery: current status and future perspective

et al. 2013

View full text Add to dashboard Cite

Now a day's intranasal (i.n) drug delivery is emerging as a reliable method to bypass the bloodbrain barrier (BBB) and deliver a wide range of therapeutic agents including both small and large molecules, growth factors, viral vectors and even stem cells to the brain and has shown therapeutic effects in both animals and humans. This route involves the olfactory or trigeminal nerve systems which initiate in the brain and terminate in the nasal cavity at the olfactory neuroepithelium or respiratory epithelium. They are the only externally exposed portions of the central nervous system (CNS) and therefore represent the most direct method of noninvasive entry into the brain. This approach has been primarily used to explore therapeutic avenues for neurological diseases. The potential for treatment possibilities with olfactory transfer of drugs will increase as more effective formulations and delivery devices are developed. Recently, the apomorphine hydrochloride dry powders have been developed for i.n. delivery (Apomorphine nasal, Lyonase technology, Britannia Pharmaceuticals, Surrey, UK). The results of clinical trial Phase III suggested that the prepared formulation had clinical effect equivalent to subcutaneously administered apomorphine. In coming years, intranasal delivery of drugs will demand more complex and automated delivery devices to ensure accurate and repeatable dosing. Thus, new efforts are needed to make this noninvasive route of delivery more efficient and popular, and it is also predicted that in future a range of intranasal products will be used in diagnosis as well as treatment of CNS diseases. This review will embark the existing evidence of nose-to-brain transport. It also provides insights into the most relevant pre-clinical studies of direct nose-brain delivery and delivery devices which will provide relative success of intranasal delivery system. We have, herein, outlined the relevant aspects of CNS drugs given intranasally to direct the brain in treating CNS disorders like Alzheimer's disease, depression, migraine, schizophrenia, etc.

show abstract

Section: Rivastigminementioning

confidence: 99%

Insights into direct nose to brain delivery: current status and future perspective

et al. 2013

View full text Add to dashboard Cite

show abstract

“…In this case, poly(n-butylcyanoacrylate) nanoparticles were prepared by emulsion polymerization method and coated with 1% polysorbate 80 to target deliver rivastigmine into the brain [96]. Rivastigmine is an established noncompetitive and reversible inhibitor of both acetylcholinesterase and butyryl cholinesterase [97], indicated for the treatment of mild to moderate dementia of the Alzheimer's type.…”

Section: Nanoparticles For Rivastigmine Deliverymentioning

confidence: 99%

Brain Drug Delivery Systems for Neurodegenerative Disorders

Garbayo

Ansorena

Blanco-Prieto

2012

CPB

View full text Add to dashboard Cite

Neurodegenerative disorders (NDs) are rapidly increasing as population ages. However, successful treatments for NDs have so far been limited and drug delivery to the brain remains one of the major challenges to overcome. There has recently been growing interest in the development of drug delivery systems (DDS) for local or systemic brain administration. DDS are able to improve the pharmacological and therapeutic properties of conventional drugs and reduce their side effects. The present review provides a concise overview of the recent advances made in the field of brain drug delivery for treating neurodegenerative disorders. Examples include polymeric micro and nanoparticles, lipidic nanoparticles, pegylated liposomes, microemulsions and nanogels that have been tested in experimental models of Parkinson's, Alzheimer's and Hungtinton's disease. Overall, the results reviewed here show that DDS have great potential for NDs treatment.

show abstract

“…Mostly the cause is Idiopathic. Mutation in chromosome 4 and 6 is the main origin for Parkinsonism [1,2]. Dopamine is a neurotransmitter which is feasible in performing the functions of lokomotion, learning, working, memory, cognition, and emotion.…”

Section: Introductionmentioning

confidence: 99%

Pramipexole Dihydrochloride Loaded Mpegpcl Nanosuspension by Modified Nanoprecipitation: In Vitro and in Vivo Evaluation

Sundaram

2016

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective: Nanosuspension in drug delivery is known to improve solubility, dissolution, and eventually bioavailability of the drugs in the brain. This study was carried out to show the neuroprotective effect of pramipexole dihydrochloride nanosuspension for the potential treatment in Parkinson's disease and to evaluate the effectiveness in both in vitro and in vivo models.Methods: Nanosuspension of pramipexole dihydrochloride was prepared with methoxy polyethylene glycol-poly (caprolactone) (MPEG-PCL) and Pluronic F68 by the process of modified nanoprecipitation technique with different concentrations of MPEG-PCL. The particle size, zeta potential, scanning electron microscopy (SEM), transmission electron microscopy (TEM), and in vitro drug release were performed. The cell viability study was performed using SH-SY5Y cells. Further, the formulation is evaluated for its antioxidant potential against rotenone-induced neuronal damage in male Wister rats such as enzymatic, non-enzymatic antioxidants, and histopathological evaluation.Result: The nanoformulation shows least particle size of 143 nm and maximum zeta potential value of 33.4 mv with 88.53% entrapment efficiency were observed with PMPNP 2 formulation. The SEM, TEM, and in vitro drug release of PMPNP 2 were showed spherical shape with controlled release when compared to other formulations. Further, the MTT assay was performed using SH-SY5Y cells which show more than 50% cell viability with 50 μl of PPMNP 2 nanoformulation. Moreover, the antioxidant potential done in rotenone-induced neuronal damage in Wister rats. The results showed elevation in the levels of enzymatic and non-enzymatic antioxidants compared with the neuronal toxic group, and the nanoformulation group showed a decrease in levels of lipid peroxidation which correlates with histopathological architecture. Conclusion:This study concluded that our nanoformulation shows a significant advantage of neuroprotective effect than the plain formulation for the treatment of Parkinson's disease in both in vitro and in vivo studies.

show abstract

Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease

Cited by 334 publications

References 64 publications

Insights into direct nose to brain delivery: current status and future perspective

Insights into direct nose to brain delivery: current status and future perspective

Brain Drug Delivery Systems for Neurodegenerative Disorders

Pramipexole Dihydrochloride Loaded Mpegpcl Nanosuspension by Modified Nanoprecipitation: In Vitro and in Vivo Evaluation

Contact Info

Product

Resources

About